Loss of CD20 Expression and Exhaustion of Effector Cells Limit ADCC in CLL Patients Treated with Rituximab.

被引：1
|
作者：
Vire, Berengere [1 ]
Perry, Justin S. A. [2 ]
Lee, Elinor [1 ]
Stennett, Lawrence S. [1 ]
Samsel, Leigh [3 ]
McCoy, Philip [3 ]
Wilson, Wyndham H. [4 ]
Bielekova, Bibiana [2 ]
Wiestner, Adrian [1 ]
机构：
[1] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
[2] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
[3] NHLBI, Flow Cytometry Core Facil, NIH, Bethesda, MD 20892 USA
[4] NCI, CCR, NIH, Bethesda, MD 20892 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
10.1182/blood.V114.22.1610.1610
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：643 / 644
页数：2
相关论文
共 50 条
  • [1] Loss of CD20 expression on CLL cells following treatment with rituximab
    Poirot, Brigitte
    Chedani, Hicham
    Abbed, Karim
    Tertian, Gerard
    Raphael, Martine
    Besson, Caroline
    HEMATOLOGIE, 2010, 16 (01): : 92 - 95
  • [2] Modulation of CD20 expression in B-cell lymphomas treated with rituximab.
    Seliem, RM
    Freeman, JK
    Hasserjian, RP
    BLOOD, 2002, 100 (11) : 311B - 311B
  • [3] Restoration of rituximab sensitivity in CD20 negative B-Cell lymphoma, cells; Epigenetic change of CD20 expression after treatment of rituximab.
    Tomita, Akihiro
    Hiraga, Junji
    Kiyoi, Hitoshi
    Kinoshita, Tomohiro
    Naoe, Tornoki
    BLOOD, 2006, 108 (11) : 155B - 155B
  • [4] Loss of CD20 expression in relapsed lymphomas after rituximab therapy
    Haidar, JH
    Shamseddine, A
    Salem, Z
    Mrad, YA
    Nasr, MR
    Zaatari, G
    Bazarbachi, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (05) : 330 - 332
  • [5] CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells
    Kretschmer, Anna
    Lohse, Stefan
    Rosner, Thies
    Jansen, Marco J. H.
    Kellner, Christian
    Peipp, Matthias
    Cragg, Mark S.
    Alsadeq, Ameera
    Schewe, Denis M.
    Leusen, Jeanette H. W.
    Valerius, Thomas
    BLOOD, 2016, 128 (22)
  • [6] Microenvironmental interactions up-regulate CD20 expression in CLL B cells, but confer resistance to rituximab
    Pavlasova, Gabriela
    Borsky, Marek
    Seda, Vaclav
    Cerna, Katerina
    Osickova, Jitka
    Mayer, Jiri
    Pospisilova, Sarka
    Davids, Matthew
    Brown, Jennifer
    Mraz, Marek
    LEUKEMIA & LYMPHOMA, 2015, 56 : 76 - 77
  • [7] Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL
    Marquez, Maria-Elena
    Hernandez-Uzcategui, Octavio
    Cornejo, Alejandro
    Vargas, Paula
    Da Costa, Osiris
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (02) : 211 - 218
  • [8] Comparison of the in vitro effects of the CD20 antibodies rituximab and GA101 on CLL cells
    Patz, M.
    Forcob, N.
    Isaeva, P.
    Klein, C.
    Umana, P.
    Wendtner, C.
    Hallek, M.
    Krause, G.
    ONKOLOGIE, 2010, 33 : 239 - 239
  • [9] Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression
    Shimada, Kazuyuki
    Tomita, Akihiro
    Saito, Shigeki
    Kiyoi, Hitoshi
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (03) : 455 - 457
  • [10] The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo
    Scialdone, Annarita
    Hasni, Muhammad Sharif
    Damm, Jesper Kofoed
    Lennartsson, Andreas
    Gullberg, Urban
    Drott, Kristina
    ONCOTARGET, 2017, 8 (23) : 37409 - 37422
12345